Astellas Pharma. has filed a patent for methods of generating and expanding human hemangio-colony forming cells in vitro. These methods allow for the production of large numbers of these cells, which can be used for various research, clinical, and therapeutic applications. GlobalData’s report on Astellas Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Astellas Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. Astellas Pharma's grant share as of September 2023 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Methods for generating and expanding human hemangio-colony forming cells
A recently filed patent (Publication Number: US20230313141A1) describes a method for generating human embryonic stem cell-derived hemangio-colony forming cells in vitro. The method involves several steps to promote the formation and differentiation of these cells.
The method begins by culturing human embryonic stem cells in a serum-free media containing vascular endothelial growth factor (VEGF) and bone morphogenic protein 4 (BMP-4) to promote the formation of embryoid bodies. These embryoid bodies are then cultured in a serum-free media containing at least two growth factors selected from VEGF, BMP-4, and basic fibroblast growth factor (bFGF), which further promotes their development.
Afterwards, the embryoid bodies are disaggregated into single cells, which are then cultured in a serum-free media containing at least two growth factors selected from insulin, transferrin, granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), interleukin-6 (IL-6), granulocyte colony-stimulating factor (G-CSF), stem cell factor (SCF), thrombopoietin (TPO), FLT3 (FL), VEGF, and BMP-4. This step leads to the generation of human hemangio-colony forming cells.
The culturing in all the steps can be performed under low attachment conditions, and the serum-free media used in step (a), (b), and/or (d) may also contain erythropoietin (EPO), a HOXB4 protein, or methylcellulose. Additionally, the serum-free media used in step (b) may contain growth factors such as SCF, FL, TPO, and EPO.
The method also includes optional steps for purifying and isolating the generated hemangio-colony forming cells. Purification can be achieved using immunoaffinity column chromatography with an anti-CD71 antibody, while isolation can be based on size and/or morphology.
Furthermore, the embryonic stem cells used in the method can be from a library of cells that are hemizygous or homozygous for at least one major histocompatibility (MHC) allele present in the human population. This allows for the generation of a library of human hemangio-colony forming cells that are hemizygous or homozygous for MHC alleles, with each member having a unique set of MHC alleles compared to other members of the library.
The resulting human embryonic stem cell-derived hemangio-colony forming cells have the potential to differentiate into hematopoietic cells and endothelial cells. The method also provides the option to further differentiate these cells into human hematopoietic cells or human endothelial cells.
Overall, this patent presents a detailed method for generating human hemangio-colony forming cells from embryonic stem cells, offering potential applications in regenerative medicine and research.
To know more about GlobalData’s detailed insights on Astellas Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
